Abernethy D R, Greenblatt D J, Ameer B, Shader R I
J Pharmacol Exp Ther. 1985 Aug;234(2):345-9.
Eleven subjects received acetaminophen (650 mg i.v.) on two occasions in random sequence, with and without concurrent administration of probenecid (500 mg) every 6 hr. Nine subjects similarly received lorazepam (2 mg. i.v.) with and without concurrent probenecid. Acetaminophen half-life was prolonged during probenecid treatment (mean +/- S.E., 4.30 +/- 0.23 vs. 2.51 +/- 0.16 hr; P less than .001) due to markedly decreased clearance (178 +/- 13 vs. 329 +/- 24 ml/min; P less than .001) with no change in volume of distribution (65 +/- 4 vs. 69 +/- 3 l; NS). Urinary excretion of acetaminophen glucuronide during 24 hr was decreased (84 +/- 9 vs. 260 +/- 21 mg of acetaminophen as glucuronide; P less than .001) and acetaminophen sulfate excretion was increased (323 +/- 25 vs. 217 +/- 17 mg of acetaminophen as sulfate; P less than .005) during concurrent probenecid treatment. However, the sum of the two conjugated metabolites was not significantly different (407 +/- 28 vs. 476 +/- 20 mg of acetaminophen as glucuronide plus sulfate excreted per 24 hr; NS). Lorazepam half-life was also prolonged during probenecid treatment (33.0 +/- 3.9 vs. 14.3 +/- 1.08 hr; P less than .001) due to decreased clearance (44.7 +/- 5.4 vs. 80.3 +/- 13.2 ml/min; P less than .001) with no change in volume of distribution (111 +/- 5 vs. 111 +/- 7 l; NS). Formation of the ether glucuronides of acetaminophen and lorazepam is impaired markedly by therapeutic doses of probenecid. Sulfate conjugation is not affected.(ABSTRACT TRUNCATED AT 250 WORDS)
11名受试者分两次随机接受对乙酰氨基酚(静脉注射650毫克),一次同时每6小时服用丙磺舒(500毫克),另一次不服用。9名受试者同样分两次接受劳拉西泮(静脉注射2毫克),一次同时服用丙磺舒,另一次不服用。在丙磺舒治疗期间,对乙酰氨基酚的半衰期延长(平均值±标准误,4.30±0.23小时对2.51±0.16小时;P<0.001),原因是清除率显著降低(178±13对329±24毫升/分钟;P<0.001),而分布容积无变化(65±4对69±3升;无显著性差异)。在丙磺舒同时治疗期间,24小时内对乙酰氨基酚葡萄糖醛酸苷的尿排泄量减少(84±9对260±21毫克对乙酰氨基酚葡萄糖醛酸苷;P<0.001),对乙酰氨基酚硫酸盐排泄量增加(323±25对217±17毫克对乙酰氨基酚硫酸盐;P<0.005)。然而,两种结合代谢物的总量无显著差异(每24小时排泄的对乙酰氨基酚葡萄糖醛酸苷加硫酸盐为407±28对476±20毫克;无显著性差异)。在丙磺舒治疗期间,劳拉西泮的半衰期也延长(33.0±3.9对14.3±1.08小时;P<0.001),原因是清除率降低(44.7±5.4对80.3±13.2毫升/分钟;P<0.001)而分布容积无变化(111±5对111±7升;无显著性差异)。治疗剂量的丙磺舒显著损害对乙酰氨基酚和劳拉西泮的醚葡萄糖醛酸苷的形成。硫酸盐结合不受影响。(摘要截短至250字)